This finding, along with the observation that Bevacizumab increases toxicity of standard chemotherapy in this trial, resulted in the FDA withdrawing approval for Bevacizumab for combination treatment of metastatic Her2/neu negative breast cancer in 2011 (53). The gene discussed is ERBB2; the disease is breast carcinoma.